Trends in clinical trials in surgical oncology: Implications for outcomes research

Clinical Therapeutics

Volumn 25, Issue 2, 2003, Pages 684-698

  Guller, Ulrich ^a   Blumenstein, Brent A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Outcomes assessment; Quality of life; Surgical oncology

Indexed keywords

ACCURACY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE; HUMAN; MEDICAL RESEARCH; METHODOLOGY; ONCOLOGY; QUALITY OF LIFE; REGULATORY MECHANISM; TREATMENT OUTCOME;

EID: 0037292272     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80105-4     Document Type: Article

References (45)

1. Outcomes and the management of health care. Health Services Research Group. CMAJ. 1992;147:1775-1780.
2. Brenneman FD, Wright JG, Kennedy ED, McLeod RS. Outcomes research in surgery. World J Surg. 1999;23:1220-1223.
3. Iezzoni LI, Shwartz M, Ash AS, et al. Risk adjustment methods can affect perceptions of outcomes. Am J Med Qual. 1994;9:43-48.
4. Hulley SB, Cummings SR, Warren SB, et al. Conceiving the research question. In: Hiscock TY, Murphy JA, Vassiliou JC, eds. Designing Clinical Research. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:17-23.
5. American College of Surgeons Oncology Group Web site. Available at: http://www.acosog.org/. Accessed December 6, 2002.
6. Lorenz W, Troidl H, Solomkin JS, et al. Second step: Testing-outcome measurements. World J Surg. 1999;23:768-780.
7. Epstein AM. The outcomes movement - will it get us where we want to go? N Engl J Med. 1990;323:266-270.
8. Wood-Dauphinee S, Troidl H. Endpoints for clinical studies: Conventional and innovative variables. In: Troidl H, Spitzer WO, McPeek B, et al, eds. Principles and Practice of Research: Strategies for Surgical Investigators. New York, NY: Springer; 1991:53-68
9. Lorenz W. Outcome: Definition and methods of evaluation. In: Troidl H, Spitzer WO, McPeek B, et al, eds. Surgical Research: Basic Principles and Clinical Practice. 3rd ed. New York: Springer; 1998: 513-520.
10. Wright JG. Outcomes research: What to measure. World J Surg. 1999;23:1224-1226.
11. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med. 1998;17:517-532.
12. Cella DF, Lloyd SR, Wright BD. Cross-cultural instrument equating: Current research and future directions. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:707-715.
13. Wagner K, Koller M, Keil A, et al. Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment [in German]. Chirurg. 1998;69:252-258.
14. Koller M, Kussmann J, Lorenz W, Rothmund M. Measuring quality of life in after-care of tumor surgery. Methods, problems and applications [in German]. Chirurg. 1994;65:333-339.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
16. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-629.
17. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
18. D'Amico AV, Vogelzang NJ. Prostate brachytherapy: Increasing demand for the procedure despite the lack of standardized quality assurance and long term outcome data. Cancer. 1999;86:1632-1634.
19. Eschwege F. Localized cancer of the prostate. What to tell the patient? Cancer Radiother. 2002;6:137-140.
20. Klein EA, Kupelian PA, Dreicer R, et al. Locally advanced prostate cancer. Curr Treat Options Oncol. 2001;2:403-411.
21. Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patient survey. Cancer. 1998;83:1362-1368.
22. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:417-424.
23. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765-769.
24. Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg. 2001;88:325-337.
25. Rumstadt B, Schwab M, Schuster K, et al. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J Gastrointest Surg. 1997;1:245-250.
26. Gontero P, Tizzani A, Muir GH, et al. The genetic alterations in the oncogenic pathway of transitional cell carcinoma of the bladder and its prognostic value. Urol Res. 2001;29:377-387.
27. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15:1553-1559.
28. Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002;89:327-334.
29. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998;339:223-228.
30. Soeth E, Roder C, Juhl H, et al. The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer. 1996;69:278-282.
31. Vogel I, Kruger U, Marxsen J, et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: A new prognostic factor. Clin Cancer Res. 1999;5:593-599.
32. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer. 1997;80:1188-1197.
33. Guidelines for monitoring of clinical trials for cooperative groups, CCOP research bases, and the Cancer Trials Support Unit (CTSU). Section 2: Roles and responsibilities for the conduct of quality assurance programs. Available at: http://ctep.cancer.gov/monitoring/section2.html. Accessed December 4, 2002.
34. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409-422.
35. Ross MI, Balch CM. Surgical treatment of primary melanoma. In: Balch C, Houghton AN, Sober AJ, Soong SJ, eds. Cutaneous Melanoma. 3rd ed. St. Louis, Mo: Quality Medical Publishing; 1998:141-153.
36. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262-267.
37. Blumenthal R, Banic A, Brand CU, et al. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. Swiss Surg. 2002;8:209-214.
38. Bogle M, Kelly P, Shenaq J, et al. The role of soft tissue reconstruction after melanoma resection in the head and neck. Head Neck. 2001;23:8-15.
39. Clinton B, Gore A. Reinventing the regulation of cancer drugs. Accelerating approval and expanding access. National Performance Review. March 1996. Available at: http://www.fda.gov/cber/pubinfo/roboguide.pdf. Accessed December 6, 2002.
40. D'Agostino RB Jr. Debate: The slippery slope of surrogate outcomes. Curr Control Trials Cardiovasc Med. 2000;1:76-78.
41. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125:605-613.
42. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282:786-790.
43. SEER Cancer Statistics Review; 1992-1997. Available at: http://seer.cancer.gov/Publications/CSR1973_1998/. Accessed December 6, 2002.
44. Goad JR, Chang SJ, Ohori M, Scardino PT. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am. 1993;20:727-736.
45. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Followup. J Urol. 1993;149:519-522.